Sean Nolan

1.1

4.2

4.4

Position	Company	Period
Director	Neurogene Inc	Feb. 1, 2015 -
Executive Vice President, Chief Business Officer	InterMune Inc	Feb. 14, 2013 -
President, Chief Executive Officer	AveXis Inc	May 15, 2018 -
President, Chief Executive Officer, Director	AveXis Inc	June 1, 2015 - May 15, 2018

Terry Kearney Paul Manning Daniel Welch

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Download results Settings

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	Company	B/S Transaction type	Nb. shares Price Value	Number of shares	Price	Value
2026-01-27	2026-01-26	Taysha Gene Therapies Inc (TSHA)	S Sale	43,996 -17.7% 195.39 US$1,834,300	43,996 -17.7%	195.39	US$1,834,300
2026-01-27	2026-01-23	Taysha Gene Therapies Inc (TSHA)	S Sale	46,794 +34.4% 422.78 US$1,929,902	46,794 +34.4%	422.78	US$1,929,902
2026-01-23	2026-01-23	Taysha Gene Therapies Inc (TSHA)	PrS Proposed sale	84,282 229.81 US$4,314,730	84,282	229.81	US$4,314,730
2023-08-16	2023-08-16	Taysha Gene Therapies Inc (TSHA)	B Purchase	444,444 +40.7% 0.90 US$400,000	444,444 +40.7%	0.90	US$400,000
2021-05-24	2021-05-20	Taysha Gene Therapies Inc (TSHA)	B Purchase	1,170 +inf% 22.35 US$26,150	1,170 +inf%	22.35	US$26,150